InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,070.55
(
1.20%
)
US TECH 100
17,002.80
(
0.00%
)
Dow Jones
38,503.69
(
0.69%
)
Brent Oil
87.74
(
0.19%
)
Bitcoin
66,637.28
(
0.34%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 309

Monday, 08/20/2018 9:29:27 AM

Monday, August 20, 2018 9:29:27 AM

Post# of 438
IOVA focuses on TIL therapy in Metastatic Melanoma and has a relatively long cash runway.

IOVA is presently enrolling a Ph2 trial in Metastatic Melanoma

If the bloom continues to fade on CART-T therapies, the equity market may pay more attention to TIL

At present the burn rate, IOVA's cash runway extends into 2022.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up